The evaluation of healing effect of Rebamipide for patients with artificial ulcer after ESD

The evaluation of healing effect of Rebamipide for patients with artificial ulcer after ESD - The evaluation of healing effect of Rebamipide for patients with artificial ulcer after ESD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003001

Enrollment

Registered

2010-01-09

Start date

2006-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early gastric cancers treated by ESD

Interventions

The PPI group administered with rabeprazole 20mg daily for 8 weeks The combination group administered rebamipide 300mg daily for 8 weeks with rabeprazole 20mg daily.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: differenciated gastric cancers with no lymphatic -vascular involvement corrlating with a normal risk of lymph node metastasis were defined as: mucosal cancer without ulcer findings irrespective of tumor size; mucosal cancer with ulcer findings less than 30mm in diameter

Exclusion criteria

Exclusion criteria: EGCs which did not fall into one of the categories were excluded from the study and the patients were urged to receive a gastrectomy with removal of lymph nodes.

Design outcomes

Primary

Measure	Time frame
The progressing ratio to the Scar-stage and ulcer residual ratio between 2 and 56 days after ESD compared with the PPI and the combination group.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026